The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.
Sherene Loi
No relevant relationships to disclose
Stefan Michiels
No relevant relationships to disclose
Diether Lambrechts
No relevant relationships to disclose
Roberto Salgado
No relevant relationships to disclose
Nicolas Sirtaine
No relevant relationships to disclose
Debora Fumagalli
No relevant relationships to disclose
Bart Claes
No relevant relationships to disclose
Pirkko-Liisa Kellokumpu-Lehtinen
No relevant relationships to disclose
Petri Bono
No relevant relationships to disclose
Vesa V Kataja
No relevant relationships to disclose
Denis Larsimont
No relevant relationships to disclose
Martine J. Piccart-Gebhart
No relevant relationships to disclose
Heikki Joensuu
No relevant relationships to disclose
Christos Sotiriou
No relevant relationships to disclose